Launch the RSV vaccine mRNA-1345 in 2024
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Aug 2023
- Due
- 31 Dec 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company continues to expect a 2024 launch of its RSV vaccine with a potential best-in-class profile”
What we found
Evidence strength A What the grades mean
A later 10-Q states Moderna launched commercial sales of its RSV vaccine in the third quarter of 2024, within the 2024 deadline. The exact launch date is not given.
-
A Moderna 10-Q filed 2025-05-01
“We launched commercial sales of our RSV vaccine in the third quarter of 2024.” ✓ confirmed on the page
-
A Moderna 10-Q filed 2025-05-01
“In May 2024, the U.S. Food and Drug Administration (FDA) approved mRESVIA® (mRNA-1345), our mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.” ✓ confirmed on the page
Market reaction: the shares moved -4.1% against the S&P 500 over the three sessions around the disclosure (30 Apr 2025 to 5 May 2025). What this measures
Checked 10 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift -31 days
- Language weakened: expected → aspirational
- 2 versions
-
Version 1 · original · stated 3 Aug 2023
Deadline 31 Dec 2024 (“a 2024 launch”) · wording expected
-
Version 2 · stated 2 May 2024
Deadline 30 Nov 2024 (“fall 2024”) · wording aspirational
“Moderna is targeting fall 2024 for its U.S. RSV vaccine launch”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- RSV vaccine mRNA-1345 launch
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-MRNA-006205 · Corrections policy